KPI data tables
Cigna operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | MCR |
|---|---|
| Q3 2026 | 85 |
| Q2 2026 | 84.5 |
| Q1 2026 | 79.8 |
| Q4 2025 | 88 |
| Q3 2025 | 84.8 |
| Q2 2025 | 83.2 |
| Q1 2025 | 82.2 |
| Q4 2024 | 87.9 |
| Q3 2024 | 82.8 |
| Q2 2024 | 82.3 |
| Q1 2024 | 79.9 |
| Q4 2023 | 82.2 |
| Q3 2023 | 80.5 |
| Q2 2023 | 81.2 |
| Q1 2023 | 81.3 |
Source: The Cigna Group quarterly financial-supplement Cigna Healthcare Premium Revenue and Medical Care Ratio tables. Q3 2026 85.0% and Q3 2025 84.8%: 5 Nov 2026 Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1739940/000114036126042030/ef20084818_ex99-1.htm. Q2 2026 84.5% and Q2 2025 83.2%: Q2 2026 supplement https://s202.q4cdn.com/757723766/files/doc_earnings/2026/q2/supplemental-info/2Q26-financial-supplement.pdf and 30 Jul 2026 Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1739940/000114036126030135/ef20078875_ex99-1.htm. Q1 2026 79.8% and Q1 2025 82.2%: Q1 2026 supplement. Q4 2025 88.0% and FY 2025 84.4%: Q4 2025 supplement. Q3 2025 84.8% and Q3 2024 82.8%: Q3 2025 supplement. Q2 2024 82.3% and Q2 2023 81.2%: Q2 2024 supplement. Q1 2024 79.9% and Q1 2023 81.3%: Q1 2024 supplement. Q4 2024 87.9%, FY 2024 83.2%, Q4 2023 82.2%, FY 2023 81.3%: Q4 2024 supplement. Q3 2023 80.5%: Q3 2024 supplement prior-year column.
| Period | Insured | Administrative services only |
|---|---|---|
| 2025 | 3.808 | 14.31 |
| 2024 | 5.064 | 14.083 |
| 2023 | 5.464 | 14.316 |
Source: The Cigna Group Form 10-K Cigna Healthcare medical customers by funding type (lives in thousands, divided by 1,000 here). FY 2025 insured 3,808 and ASO 14,310. FY 2024 insured 5,064 and ASO 14,083. FY 2023 insured 5,464 and ASO 14,316. 10-K year ended 31 Dec 2025 (acc 0001739940-26-000006) https://www.sec.gov/Archives/edgar/data/1739940/000173994026000006/ci-20251231.htm. Insured is U.S. Healthcare insured plus International Health insured. ASO is U.S. Healthcare ASO plus International Health ASO. Q2 2026 2,439 U.S. insured + 1,262 International insured and 14,239 U.S. ASO + 473 International ASO: Q2 2026 supplement page 7 https://s202.q4cdn.com/757723766/files/doc_earnings/2026/q2/supplemental-info/2Q26-financial-supplement.pdf.
| Period | Total medical customers |
|---|---|
| Q3 2026 | 18.452 |
| Q2 2026 | 18.413 |
| Q1 2026 | 18.334 |
| Q4 2025 | 18.118 |
| Q3 2025 | 18.059 |
| Q2 2025 | 18.046 |
| Q1 2025 | 18.043 |
| Q4 2024 | 19.147 |
| Q3 2024 | 19.048 |
| Q2 2024 | 19.043 |
| Q1 2024 | 19.184 |
| Q4 2023 | 19.78 |
| Q3 2023 | 19.607 |
| Q2 2023 | 19.506 |
| Q1 2023 | 19.473 |
Source: The Cigna Group earnings-release and quarterly financial-supplement customer relationship tables (lives in thousands, divided by 1,000 here). Q3 2026 18,452 and Q3 2025 18,059: 5 Nov 2026 Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1739940/000114036126042030/ef20084818_ex99-1.htm. Q2 2026 18,413 and Q2 2025 18,046: 30 Jul 2026 results https://newsroom.thecignagroup.com/2026-07-30-The-Cigna-Group-Reports-Strong-Second-Quarter-2026-Results,-Raises-2026-Outlook and Q2 2026 supplement https://s202.q4cdn.com/757723766/files/doc_earnings/2026/q2/supplemental-info/2Q26-financial-supplement.pdf. Q1 2026 18,334 and Q1 2025 18,043: Q1 2026 results https://newsroom.thecignagroup.com/2026-04-30-The-Cigna-Group-Reports-Strong-First-Quarter-2026-Results,-Raises-2026-Outlook. YE 2025 18,118 and YE 2024 19,147: FY 2025 10-K customer table (acc 0001739940-26-000006). Q3 2025 18,059: Q3 2025 results https://newsroom.thecignagroup.com/2025-10-30-The-Cigna-Group-Reports-Strong-Third-Quarter-2025-Results,-Reaffirms-2025-Adjusted-EPS-Outlook. Q2 2024 19,043: Q2 2025 supplement prior-year column. Q1 2024 19,184 and Q1 2023 19,473: Q1 2024 supplement. Q3 2024 19,048 and Q3 2023 19,607: Q3 2024 supplement. Q2 2023 19,506: Q2 2024 supplement. YE 2023 19,780: FY 2023 supplement.
| Period | Pharmacy claim volume |
|---|---|
| 2025 | 2,222 |
| 2024 | 2,120 |
| 2023 | 1,585 |
| 2022 | 1,575 |
Source: The Cigna Group Form 10-K Evernorth pharmacy claim volume table. FY 2025 2,222, FY 2024 2,120, FY 2023 1,585: 10-K year ended 31 Dec 2025 (acc 0001739940-26-000006) https://www.sec.gov/Archives/edgar/data/1739940/000173994026000006/ci-20251231.htm and Q4 2025 financial supplement https://s202.q4cdn.com/757723766/files/doc_earnings/2025/q4/supplemental-info/4Q25-financial-supplement.pdf. FY 2022 1,575: 10-K year ended 31 Dec 2024 (acc 0001739940-25-000009). H1 2026 1,064 (Q1 527, Q2 537) is year-to-date only and is not plotted: Q2 2026 supplement https://s202.q4cdn.com/757723766/files/doc_earnings/2026/q2/supplemental-info/2Q26-financial-supplement.pdf.
| Period | Total pharmacy customers |
|---|---|
| Q3 2026 | 117.698 |
| Q2 2026 | 118.243 |
| Q1 2026 | 121.02 |
| Q4 2025 | 123.603 |
| Q3 2025 | 122.486 |
| Q2 2025 | 121.892 |
| Q1 2025 | 122.283 |
| Q4 2024 | 118.304 |
| Q3 2024 | 119.996 |
| Q2 2024 | 122.47 |
| Q1 2024 | 122.767 |
| Q4 2023 | 98.57 |
| Q3 2023 | 98.325 |
| Q2 2023 | 98.638 |
| Q1 2023 | 98.749 |
Source: The Cigna Group earnings-release and quarterly financial-supplement customer relationship tables (lives in thousands, divided by 1,000 here). Q3 2026 117,698: 5 Nov 2026 Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1739940/000114036126042030/ef20084818_ex99-1.htm. Q2 2026 118,243, Q1 2026 121,020, Q2 2025 121,892, YE 2025 123,603: Q2 2026 results https://newsroom.thecignagroup.com/2026-07-30-The-Cigna-Group-Reports-Strong-Second-Quarter-2026-Results,-Raises-2026-Outlook and Q2 2026 supplement https://s202.q4cdn.com/757723766/files/doc_earnings/2026/q2/supplemental-info/2Q26-financial-supplement.pdf. Q1 2025 122,283: Q1 2026 supplement. Q3 2025 122,486: Q3 2025 results https://newsroom.thecignagroup.com/2025-10-30-The-Cigna-Group-Reports-Strong-Third-Quarter-2025-Results,-Reaffirms-2025-Adjusted-EPS-Outlook. YE 2024 118,304 and YE 2023 98,570: FY 2025 10-K. Q1 2024 122,767 and Q1 2023 98,749: Q1 2024 supplement. Q2 2024 122,470 and Q2 2023 98,638: Q2 2024 supplement. Q3 2024 119,996 and Q3 2023 98,325: Q3 2024 supplement.